Foamix Pharmaceuticals Ltd.
2 Holzman Street, Weizmann Science Park
Rehovot 7670402, Israel
March 10, 2017
BY EDGAR
Suzanne Hayes
Assistant Director
Securities and Exchange Commission
Office of Healthcare and Insurance
100 F Street, N.E.
Washington, DC 20549
| |
Re:
|
Foamix Pharmaceuticals Ltd.
Registration Statement on Form F-3
(File No. 333-216224)
|
Dear Ms. Hayes:
Pursuant to Rule 461 under the Securities Act of 1933 (the “Securities Act”), Foamix Pharmaceuticals Ltd. hereby requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission so that the Registration Statement, as amended, will become effective under the Securities Act at 5:00 p.m. ET on March 14, 2017 or as soon thereafter as practicable.
We request that we be notified of such effectiveness by a telephone call to Andrea L. Nicolas of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-3416 and that such effectiveness also be confirmed in writing.
| |
Very truly yours,
FOAMIX PHARMACEUTICALS LTD.
|
|
| |
|
|
|
|
/s/ Ilan Hadar |
|
| |
By:
|
Ilan Hadar |
|
| |
Title: |
Chief Financial Officer |
|
| |
|
|
|
|
cc:
|
Phyllis G. Korff, Esq.
Andrea L. Nicolas, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
Four Times Square
New York, NY 10036
|